We are live on
!
Find out more
CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.99B
1-Year Est. Return
737.95%
This Fund
S&P 500
This Quarter
Est. Return
+54.14%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.52B
AUM Growth
+$24M
(+1.6%)
Cap. Flow
-$83.5M
Cap. Flow
% of AUM
-5.5%
Top 10 Holdings %
Top 10 Hldgs %
56.06%
Holding
84
New
11
Increased
10
Reduced
18
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Enliven Therapeutics
ELVN
|
+$39.4M |
| 2 |
BridgeBio Pharma
BBIO
|
+$37.2M |
| 3 |
AMAM
Ambrx Biopharma Inc
AMAM
|
+$31M |
| 4 |
Protagonist Therapeutics
PTGX
|
+$28.6M |
| 5 |
Pliant Therapeutics
PLRX
|
+$18.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
+$50.1M |
| 2 |
Revolution Medicines
RVMD
|
+$45.1M |
| 3 |
Altimmune
ALT
|
+$42.8M |
| 4 |
VTYX
Ventyx Biosciences
VTYX
|
+$35.4M |
| 5 |
Amylyx Pharmaceuticals
AMLX
|
+$20.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.97% |
| 2 | Financials | 0.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Tango Therapeutics
TNGX
$4.41B
| $16.3M | 1.07% |
4,116,949
| – | – |
|
27
Sarepta Therapeutics
SRPT
$1.77B
| $15.2M | 1% |
110,000
-90,000
| -45% | -$11.7M |
|
28
Cabaletta Bio
CABA
$455M
| $15.1M | 0.99% |
1,821,739
-150,000
| -8% | -$1.4M |
|
29
Rocket Pharmaceuticals
RCKT
$394M
| $14.9M | 0.98% |
868,550
| – | – |
|
|
KRTX
30
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $14.5M | 0.96% |
80,000
-30,000
| -27% | -$5.74M |
|
31
Structure Therapeutics
GPCR
$3.78B
| $13.7M | 0.9% |
+576,373
| New | +$13.5M |
|
|
ATXS
32
DELISTED
Astria Therapeutics
ATXS
| $13.3M | 0.88% |
1,000,000
-650,000
| -39% | -$8.79M |
|
|
MORF
33
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $12.2M | 0.81% |
+325,000
| New | +$12M |
|
|
RAPT
34
DELISTED
RAPT Therapeutics
RAPT
| $11.9M | 0.79% |
+81,250
| New | +$16.4M |
|
|
CBAY
35
DELISTED
Cymabay Therapeutics
CBAY
| $11.1M | 0.73% |
+1,271,429
| New | +$10.2M |
|
36
Olema Pharmaceuticals
OLMA
$1.05B
| $10.7M | 0.7% |
3,082,000
+1,000,000
| +48% | +$4.08M |
|
37
Cytokinetics
CYTK
$10.4B
| $10.4M | 0.69% |
296,000
| – | – |
|
38
Vaxcyte
PCVX
$8.64B
| $10.3M | 0.68% |
275,000
-50,000
| -15% | -$2.12M |
|
|
LBPH
39
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $9.44M | 0.62% |
2,353,141
+234,858
| +11% | +$1.15M |
|
40
Stoke Therapeutics
STOK
$2.11B
| $9.06M | 0.6% |
1,087,807
| – | – |
|
41
Prime Medicine
PRME
$559M
| $9.03M | 0.59% |
734,350
| – | – |
|
|
LIAN
42
DELISTED
LianBio American Depositary Shares
LIAN
| $8.33M | 0.55% |
+4,250,000
| New | +$8.8M |
|
43
Cogent Biosciences
COGT
$7.24B
| $7.55M | 0.5% |
700,000
-200,000
| -22% | -$2.56M |
|
44
Pharvaris
PHVS
$2.44B
| $6.58M | 0.43% |
816,460
| – | – |
|
|
VIGL
45
DELISTED
Vigil Neuroscience
VIGL
| $6.04M | 0.4% |
616,786
| – | – |
|
46
Atea Pharmaceuticals
AVIR
$420M
| $5.18M | 0.34% |
1,547,181
| – | – |
|
|
VERV
47
DELISTED
Verve Therapeutics
VERV
| $5.05M | 0.33% |
350,000
| – | – |
|
48
Annexon
ANNX
$886M
| $4.81M | 0.32% |
+1,250,000
| New | +$6.88M |
|
49
IDEAYA Biosciences
IDYA
$3.56B
| $4.81M | 0.32% |
350,000
| – | – |
|
50
GH Research
GHRS
$2.08B
| $4.74M | 0.31% |
593,043
| – | – |
|
Similar funds
SC
RMCM
RCM
LGM
MYAM
C
TCM
BGM
Cormorant Asset Management's Q1 2023 Portfolio in Review
As of Q1 2023, Cormorant Asset Management held 84 positions worth $1.52B, up 1.6% from $1.49B the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Cormorant Asset Management withdrew a net $83.5M in Q1 2023, closing 12 positions and reducing 18 holdings. Its most notable exit was Revolution Medicines, an estimated $45.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.
Against the trend, Cormorant Asset Management opened a new position in Enliven Therapeutics worth $42.4M.
- Cormorant Asset Management's largest Q1 2023 buy was Enliven Therapeutics: 1,936,133 shares worth $42.4M.
- Cormorant Asset Management added most to BridgeBio Pharma in Q1 2023, an estimated $37.2M increase.
- Cormorant Asset Management's biggest Q1 2023 reduction was Prometheus Biosciences, Inc. Common Stock, cutting an estimated $50.1M.
- Cormorant Asset Management fully exited Revolution Medicines in Q1 2023, selling an estimated $45.1M.
- Cormorant Asset Management's ten largest holdings make up 56% of its $1.52B portfolio in Q1 2023.
- Cormorant Asset Management opened 11 new positions and closed 12 in Q1 2023.
- Cormorant Asset Management's portfolio value rose 1.6% quarter-over-quarter to $1.52B.
Based on Cormorant Asset Management's 13F filing for Q1 2023, filed 15 May 2023.